Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells

Liang,Ning; Song,Xiaoming; Xie,Jian; Xu,Deguo; Liu,Fengjun; Yu,Xinshuang; Tian,Yuan; Liu,Zhen; Qiao,Lili; Zhang,Jiandong

doi:10.3892/mmr.2014.2873

February-2015 Volume 11 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2015 Volume 11 Issue 2

Full Size Image

Article Open Access

Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells

Authors:
- Ning Liang
- Xiaoming Song
- Jian Xie
- Deguo Xu
- Fengjun Liu
- Xinshuang Yu
- Yuan Tian
- Zhen Liu
- Lili Qiao
- Jiandong Zhang
View Affiliations / Copyright

Affiliations: Division of Oncology, Department of Graduate, Weifang Medical College, Jinan, Shandong 261053, P.R. China, Department of Thoracic Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China, Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China

Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Pages: 896-902
|
Published online on: November 5, 2014

https://doi.org/10.3892/mmr.2014.2873
Expand metrics +

Abstract

Galectin-3, a β-galactoside-binding lectin, is a cell adhesion molecule involved in the regulation of tumor progression. However, the importance of galectin-3 in Eca-109 human esophageal cancer cells has not yet been elucidated. In the present study, a lentiviral vector was designed for overexpression of galectin-3 in Eca-109 cells following plasmid‑mediated transfection (Eca-109/Gal-3 cells). A negative lentiviral vector was introduced into Eca-109 cells as a control (Eca‑109/Neo cells). Western blot and reverse transcription-polymerase chain reaction analyses were used to measure the expression levels of galectin-3 protein and mRNA. The proliferation of Eca-109 cells was measured by a cell counting kit-8 assay. Eca-109 cell apoptosis was determined by Annexin V/7-amino-actinomycin double‑staining. The migration and invasion capacity of Eca-109 cells was determined by a Transwell assay. A total of >98% Eca-109 cells were transfected with the lentiviral vector harboring galectin-3, and galectin-3 expression was detected in Eca-109 cells, Eca-109/Gal-3 cells and Eca-109/Neo cells. Compared with non‑transfected and negative control Eca-109 cells, proliferation was increased significantly in the Eca-109/Gal-3 cells (P<0.05). Galectin-3 also significantly reduced Eca-109 cell apoptosis, compared with the two control groups (P=0.007 and P=0.04, respectively). Transwell migration and invasion assays revealed that significantly greater numbers of Eca-109/Gal-3 cells crossed the artificial basement membrane (55.4±3.9) compared with either the non-transfected or negative control Eca-109 cells (30.6±1.5 and 29±2.6 respectively, P<0.05). In conclusion, galectin-3 expression was significantly increased in transfected Eca-109 esophageal cancer cells, resulting in enhanced proliferation, migration and invasion, as well as reduced apoptosis. These data indicate that galectin-3 may be a potential molecular target in the treatment of esophageal cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Barondes SH, Castronovo V, Cooper DW, et al: Galectins: a family of animal β-galactoside-binding lectins. Cell. 76:597–598. 1994. View Article : Google Scholar : PubMed/NCBI
3	Leffler H, Carlsson S, Hedlund M, Qian Y and Poirier F: Introduction to galectins. Glycoconj J. 19:433–440. 2004. View Article : Google Scholar : PubMed/NCBI
4	Lotan R, Ito H, Yasui W, et al: Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer. 56:474–480. 1994. View Article : Google Scholar : PubMed/NCBI
5	Liu FT, Hsu DK, Zuberi RI, et al: Expression and function of galectin-3, a beta-galactoside binding lectin, in human monocytes and macrophages. Am J Pathol. 147:1016–1028. 1995.PubMed/NCBI
6	Takenaka Y, Fukumori T and Raz A: Galectin-3 and metastasis. Glycoconj J. 19:543–549. 2004. View Article : Google Scholar : PubMed/NCBI
7	Nakahara S, Oka N and Raz A: On the role of galectin-3 in cancer apoptosis. Apoptosis. 10:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
8	Schoeppner HL, Raz A, Ho SB and Bresalier RS: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer. 75:2818–2826. 1995. View Article : Google Scholar : PubMed/NCBI
9	Canesin G, Gonzalez-Peramato P, Palou J, et al: Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol. 31:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
10	Sakaki M, Fukumori T, Fukawa T, et al: Clinical significance of galectin-3 in clear cell renal cell carcinoma. J Med Invest. 57:152–157. 2010. View Article : Google Scholar : PubMed/NCBI
11	Knapp JS, Lokeshwar SD, Vogel U, et al: Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol. 31:351–358. 2013. View Article : Google Scholar
12	Braeuer RR, Shoshan E, Kamiya T and Bar-Eli M: The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res. 25:592–601. 2012. View Article : Google Scholar : PubMed/NCBI
13	Honjo Y, Nangia-Makker P, Inohara H and Raz A: Downregulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 7:661–668. 2001.PubMed/NCBI
14	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
15	Gaudin JC, Mehul B and Hughes RC: Nuclear localisation of wild type and mutant galectin-3 in transfected cells. Biol Cell. 92:49–58. 2000. View Article : Google Scholar : PubMed/NCBI
16	Yang RY, Rabinovich GA and Liu FT: Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 10:e172008. View Article : Google Scholar : PubMed/NCBI
17	O’Driscoll L, Linehan R, Liang YH, et al: Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res. 22:3117–3125. 2002.
18	Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002. View Article : Google Scholar
19	Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005. View Article : Google Scholar : PubMed/NCBI
20	Markowska AI, Liu FT and Panjwani N: Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med. 207:1981–1993. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yu F, Finley RL Jr, Raz A and Kim HR: Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 277:15819–15827. 2002. View Article : Google Scholar : PubMed/NCBI
22	Haudek KC, Spronk KJ, Voss PG, et al: Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta. 1800.181–189. 2010.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of galectin-3 on the behavior of Eca‑109 human esophageal cancer cells

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles